TNDM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tandem Diabetes Care Inc (TNDM) is a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock has strong positive catalysts, hedge fund buying, favorable analyst ratings with significant upside potential, and a bullish technical setup. Despite short-term risks, the long-term growth trajectory and improving profitability make it a solid investment opportunity.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 53.139, showing no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key support levels (Pivot: 20.439, R1: 21.604).
Hedge funds are significantly increasing their positions, with an 870.81% increase in buying over the last quarter.
Analysts have raised price targets, with the highest target at $56, indicating over 125% upside potential.
Transition to the pharmacy channel is expected to accelerate growth and profitability.
SwingMax signal on 2026-04-08 with a 7.55% price increase since then.
Financials show a YoY drop in net income (-178.01%) and EPS (-200.00%), indicating short-term profitability challenges.
Stock trend analysis suggests a potential short-term decline (-4.21% in the next week, -5.31% in the next month).
In Q4 2025, revenue increased by 2.74% YoY to $290.38M, and gross margin improved to 57.67% (+3.52% YoY). However, net income dropped to -$589K (-178.01% YoY), and EPS fell to -0.01 (-200.00% YoY), reflecting short-term profitability issues.
Analysts are highly optimistic, with multiple upgrades and raised price targets. The highest target is $56 (Barclays), and the average target suggests significant upside. Analysts highlight the pharmacy channel transition, accelerating growth, and margin expansion as key drivers for the stock's re-rating.
